SK Biopharmaceuticals and PanTera Partner for Stable Supply of Key Radioisotope
Belgium and Korea have long enjoyed strong ties in the pharmaceutical industry, with growing collaboration between companies in both countries. SK Biopharmaceuticals is continuing this trend with its new partnership with Belgian radioisotope producer PanTera. Together, they will secure a stable and diverse supply of Actinium-225 (Ac-225), a crucial material for the development of next-generation cancer treatments.
RPT using alpha emitters like Ac-225 is known for targeting cancer cells more effectively while minimizing harm to healthy tissue. However, the global supply of Ac-225 has been limited, so securing reliable sources is essential. SK Biopharmaceuticals has already made steps to secure this resource, with an earlier agreement with the American company TerraPower. Now, with PanTera, SK Biopharmaceuticals strengthens its supply chain, positioning itself as a leader in the RPT market.
This partnership will support the development of SK35501, a preclinical candidate, and help reduce the risks of delays in clinical trials. By diversifying its sources, SK Biopharmaceuticals is setting itself up for long-term growth and stability in the RPT field, bringing us closer to more effective cancer treatments.
You can read more about it on the following website: https://pantera-life.com/wp-content/uploads/2025/02/2025-02-25_SKBP-PanTera_Press-Releasse.pdf
